The global bronchiectasis therapeutic market was anticipated to reach a valuation of US$ 481.71 Million in the year 2022. With a steady CAGR of 6.2% from 2023 to 2033, this market is expected to reach US$ 511 Million by 2023 and US$ 932.54 Million by 2033.
The two main factors driving the market demand for bronchiectasis therapeutic throughout the predicted period are:
It is a chronic lung disease that is characterized by aberrant, irreversible bronchial dilatation and by the destruction of both the elastic and muscular tissues as a result of both acute and chronic infection. One or both lungs are damaged when these illnesses combine. High-resolution computed tomography (HRCT) scans are used to identify the damaged site. These scans reveal that the larger airways are most severely affected while the disease is not visible in the smaller airways, which is why some patients experience symptoms for a long time before receiving a diagnosis. Such advancements in the diagnosis of respiratory diseases would enable pulmonologists as well as otolaryngologists to precisely pinpoint the illness stage and offer patients the most appropriate and timely treatment and medications. During the projected period, this tendency will positively impact the growth of the bronchiectasis therapeutic market.
The growing patient population with bronchiectasis is the primary reason for the growth of the bronchiectasis therapeutic market because bronchiectasis diagnosis and treatment aid intensive care patients to live healthy lives that allow patients to save lives. One of the actions made by organizations and individuals worldwide to lessen the development of bronchiectasis is the rise in awareness initiatives for the disease. These awareness campaigns may present a chance for the bronchiectasis therapeutic market to expand.
Another important aspect driving the growth of the industry is the availability of inexpensive, off-label generic medications. Generic medications cost less than branded medications yet contain the identical active pharmaceutical ingredient (API) as branded medications. The prevalence of bronchiectasis is increasing, and the provision of such inexpensive medications will lead to a rise in treatment adoption rates, especially in emerging and impoverished nations. The market's growth prospects will further improve with the approval of these affordable generics.
Due to the increased frequency of many respiratory problems and the consequent rise in demand for the therapy of the condition, the antibiotics category held the largest market share in the market for bronchiectasis therapeutics in 2022. Parenteral antibiotics, like an aminoglycoside (tobramycin, gentamicin) and antipseudomonal synthesized penicillin, a third-generation cephalosporin, or even a fluoroquinolone, may be necessary for individuals with moderate-to-severe symptoms. The American Thoracic Society advises using a three- to four-drug therapy regimen to cure Mycobacterium Avium Complex (MAC) in bronchiectasis. This regimen should include clarithromycin, ethambutol, rifampin, and potentially streptomycin. The average length of therapy is 18 to 24 months. Such growth in the domain of antibiotics is expected to propel the market from 2023 to 2033.
Given the rising incidence of respiratory illnesses, increased drug development research and development efforts, and technological advancements in the diagnosis of bronchiectasis, North America will dominate the global market for bronchiectasis therapeutics in 2022, holding the largest market share. The CDC projects that there were 7,848 TB cases officially recorded in the USA in 2022 and that up to 13.1 million Americans had latent TB infection. The expanding number of elderly people in North America is boosting its control over the worldwide market since older age increases the risk of bronchiectasis. For example, the Census Bureau's 2021 demographic predictions show that more than 54 million Americans are 65 or older. Hence such factors will boost and open up new avenues in the regional bronchiectasis therapeutics market.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | US$ 511 Million |
| Expected Market value in 2033 | US$ 932.54 Million |
| Growth Rate (2023 to 2033) | 6.2% from 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increasing prevalence of respiratory diseases is expected to boost the growth of the global brochiectasis therapeutic market. The availability of low cost drugs off-label generics in developed and underdeveloped countries is the major factor driving the growth of the brochiectasis therapeutic market.
However, lack of approved drugs for bronchiectasis and stringent regulatory policies are expected to restrict the growth of the global bronchiectasis therapeutic market. Additionally, the high cost involved in the research and development under diagnosis of bronchiectasis and preference for substitute treatment options are factors that may also hamper the growth of the bronchiectasis therapeutic market.
The global market for bronchiectasis therapeutic market is estimated to experience a significant growth due to the increasing demand for the treatment of bronchiectasis. Based on type, the global bronchiectasis therapeutic market is segmented into antibiotics, expectorants and others. The antibiotics segment is expected to account for the highest market share in the forecast years due to the growing prevalence of several respiratory disorders.
Based on distribution channels, the bronchiectasis therapeutic market may be divided into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies and retail pharmacies are expected to contribute the largest portion of revenue in the forecast years. However, with the rapid changes in technology and growing acceptance of e-commerce by the people worldwide may lead to the growth of the online pharmacies in the forecast years.
Principal Consultant
Geographically, the bronchiectasis therapeutic market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. The North America is expected to dominate the global bronchiectasis therapeutic market due to rising prevalence of bronchoectasis, increasing research and development activities for the drug development and technology advancements for the treatment of bronchiectasis.
Europe is expected to have the second largest share in the bronchiectasis therapeutic market due to increasing prevalence of bronchiectasis therapeutic market. East Asia is expected to observe a substantial growth in the bronchiectasis therapeutic market due to availability of funds for research and development.
On the other hand, South Asia is anticipated to experience fastest growth in the bronchiectasis therapeutic market as a result of rising incidence of respiratory diseases. In the Middle East and Africa the market growth is expected to be limited due to slow economic growth, underdeveloped infrastructure and lower access to technological advancement.
Some of the players identified in the bronchiectasis therapeutic market include:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tentatively, the global bronchiectasis therapeutic market has been segmented on the basis of product type and distribution channel.
Explore Healthcare Insights
View Reports
Bronchiectasis Therapeutic Market
